Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts

Natera, Inc.

All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.
Adds Foresight's PhasED-Seq phased variant technology with LOD95 of 0.3 ppm, enhancing Signatera MRD platform.
Expands Natera's presence in lymphoma, with Foresight's CLARITY MRD assay used in three prospective trials and NCCN guideline inclusion.
Integration of phased variants into Signatera platform expected to be launched for clinical use in 2026.
Company issued 1,127,982 shares upfront and up to ~824,583 additional contingent shares; will file registration for resale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.